Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab a

Sub-indication: Genitourinary Cancer

Drug Study

Principal Investigator: Chandler Park, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.